Adaptive Biotechnologies raises 2026 MRD revenue view to $260M-$270M while targeting positive adjusted EBITDA and free cash flow by end of 2026
Adaptive Biotechnologies Corporation Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $15.23
-11% in 7d after detection
Post-detection moves
1h
—
1d
+1.8%
3d
-6.2%
7d
-11%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS